Abstract: A peptide which binds to SARS-CoV-2 and its usage are provided. The peptide which binds to SARS-CoV-2 comprises one or more structural domain comprising CDR3 consisting of an amino acid sequence of any of SEQ ID NOs: 1 to 9 or an amino acid sequence obtained by substituting at least one amino acid in the amino acid sequence with another amino acid.

Abstract: Provided is a novel compound that has an excellent ?-lactamase inhibitory effect. More specifically, provided is a compound represented by formula (1a), (1b) or (11) having an excellent ?-lactamase inhibitory effect or a pharmaceutically acceptable salt thereof. By using this compound either in combination with a ?-lactam drug or alone, a useful preventive or therapeutic agent for bacterial infections is provided. Also provided are useful preventive or therapeutic agents for treating various diseases with the combined use of the aforesaid compound and ?-lactam drugs.

Abstract: Pharmaceutical preparations, Chinese herbal preparations, foods, and other compositions may contain, as an active ingredient, an ephedra extract, an ephedrine-alkaloid-free ephedra extract, or a polymercondensed tannin derived from an ephedra extract. Such compositions may be useful for preventing or treating COVID-19 infection (COVID-19). Such compositions are preferably provided in an orally ingestible form.

Abstract: Provided is a novel compound that has an excellent ?-lactamase inhibitory effect. More specifically, provided is a compound represented by formula (1a), (1b) or (11) having an excellent ?-lactamase inhibitory effect or a pharmaceutically acceptable salt thereof. By using this compound either in combination with a ?-lactam drug or alone, a useful preventive or therapeutic agent for bacterial infections is provided. Also provided are useful preventive or therapeutic agents for treating various diseases with the combined use of the aforesaid compound and ?-lactam drugs.

Abstract: An input device includes two conductors that are sewn onto a fiber sheet and an output unit configured to determine an impedance variation in a predetermined area on the basis of a voltage value between the two conductors to which a high-frequency current is applied.

Abstract: The present invention provides a compound having a selective opioid ? receptor agonist effect. The present invention provides a pyrazolomorphinan derivative represented by general formula (1) (in the formula, (II) R1 represents a hydrogen atom, an alkyl group, a cycloalkylmethyl group, or the like, R2 represents a hydrogen atom or a hydroxy protecting group, R3 represents a hydroxy group, an alkyl group, a partially unsaturated heterocyclic group, an aryl group, a heteroaryl group, or the like; and R4 represents a hydrogen atom, an alkyl group, an aralkyl group, a cycloalkyl group, a cycloalkyl alkyl group, a saturated heterocyclic group, an aryl group, a heteroaryl group, or the like). The pyrazolomorphinan derivative can be used as an active ingredient in an analgesic, an antidepressant, an anxiolytic, or the like.

Abstract: The invention generally relates to collagen-binding agent compositions and methods of using the same. More specifically, the invention relates in part to new collagen-binding agent compositions and methods that may be used to treat damaged collagen within tissues or used to specifically target therapeutics to tissues containing undamaged or damaged collagen.

Abstract: A yarn has a first conductive yarn having conductivity, a first insulating section covering the first conductive yarn and formed of an insulating material having absorbency, and a second conductive yarn having conductivity and disposed on an outer circumferential side of the first insulating section.

Abstract: An image generation apparatus includes a plurality of electrodes, a plurality of sensor cells, and a controller configured to provide a tomographic image of a measurement object on the basis of an intensity of a magnetic field generated by an alternating current supplied via the plurality of electrodes. The controller acquires the intensity of the magnetic field via the plurality of sensor cells.

Abstract: The present invention addresses the issue of providing a norovirus component vaccine for subcutaneous, intradermal, percutaneous, or intramuscular administration which vaccine can readily immunize the target cells, an associated product of a molecular needle serving as an active ingredient of the vaccine, and a production method for the associated product. The invention provides a norovirus component vaccine containing, as an active ingredient, an associated product including a hexamer formed through bonding of two molecules of a trimer of a molecular needle represented by the following formula (1). W-L1-Xn—Y (1) [wherein W represents an amino acid sequence of P domain of the capsid protein of norovirus as an immunogen; L1 represents a first linker sequence having 0 to 100 amino acids; X represents an amino acid sequence represented by SEQ ID NO: 1; Y represents an amino acid sequence of a cell introduction domain; n is an integer of 1 to 3].

Abstract: An object of the present invention is to establish means for providing a component vaccine which can elicit immunity to a non-structural protein. The present inventors have found that the object can be attained by providing a component vaccine containing an associated product containing a trimer and/or a hexamer of a molecular needle to which a non-structural protein of a pathogenic virus is attached.

Abstract: A measurement device has a measurement belt to which a plurality of electrode pads arranged in a row and a plurality of strain gauges arranged in parallel to the plurality of electrode pads are integrally adhered and configured to be used after being wrapped around a portion serving as a measurement target of a living body; and a processor configured to: acquire an image of the portion serving as the measurement target while applying a current to the plurality of electrode pads and acquiring a voltage signal generated between the electrode pads; and estimate a contour shape of the portion serving as the measurement target and a size of the contour shape on the basis of curvature data acquired via the plurality of strain gauges.

Abstract: It is an object of the present invention to provide a transmission-blocking vaccine using an immunogenic protein which is specifically expressed in the oocyst stage of malaria parasites or a peptide fragment thereof, and an oral transmission-blocking vaccine capable of immunizing various animals involved in the malaria infectious cycle with such a vaccine. The present invention relates to a malaria transmission-blocking vaccine for oral administration containing an immunogenic protein derived from malaria parasite which is specifically expressed in the oocyst stage of malaria parasites or a peptide fragment thereof, and a method of blocking the transmission of malaria using the same.

Abstract: An aspect of the present invention is a gas product including: a gas container; and a gas composition filled in the gas container, in which the gas composition includes nitrogen monoxide, hydrogen, and an inert gas, and a concentration of the nitrogen monoxide is 20% by volume or less based on a volume of the gas composition.

Abstract: The purpose of the present invention is to provide a novel compound which has antibacterial activity against Mycobacterium avium and Mycobacterium intracellulare that are causative bacteria of MAC infection and which is different in backbone structure from known drugs for treatment of MAC infection. One aspect of the present invention relates to a compound of Formula (I) [where R1 has the same meaning as described in the specification and claims] or a salt thereof, or a solvate thereof. Another aspect of the present invention relates to a method for producing the compound of Formula (I) or a salt thereof, or a solvate thereof, and a therapeutic agent for Mycobacterium avium complex infection (MAC infection), which comprises the compound or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof as an active ingredient.

Abstract: The object is to provide a method for inducing pili formation in bacterium of genus Bifidobacterium and a method for promoting intestinal colonization of the bacterium. 3-Phenylpropionic acid and/or 3-(4-hydroxyphenyl)propionic acid are an active ingredient of a composition for inducing the pili formation in the bacterium of genus Bifidobacterium and a composition for promoting the intestinal colonization of the bacterium.

Abstract: Methods of delivering therapeutic agents by administering compositions including a bacterial collagen-binding polypeptide segment linked to the therapeutic agent to subjects in need of treatment with the therapeutic agent are provided. In these methods, the therapeutic agent is not a PTH/PTHrP receptor agonist or antagonist, basic fibroblast growth factor (bFGF) or epidermal growth factor (EGF). The bacterial collagen-binding polypeptide segment delivers the agent to sites of partially untwisted or under-twisted collagen. Methods of treating collagenopathies using a composition including a collagen-binding polypeptide and a PTH/PTHrP receptor agonist are also provided. In addition, methods of treating hyperparathyroidism, and hair loss using compositions comprising a collagen binding polypeptide and a PTH/PTHrP receptor agonist are provided. Finally, methods of reducing hair regrowth by administering a composition including a collagen binding polypeptide and a PTH/PTHrP receptor antagonist are provided.

Abstract: An object of the present invention is to provide an anti-human norovirus agent which can inhibit infection with and proliferation of human norovirus. The present inventors have found that the object can be attained through provision of an anti-human norovirus agent comprising, as an active ingredient, a fucose analog having an inhibitory action on glycosylation by fucosyltransferase (FUT). Examples of the active ingredient include a fucose analog represented by formula (III) or (IV) or a salt thereof. [In the formulas, each of formula (III) and formula (IV) represents an ?-anomer or a ?-anomer; each of R4, R3, and R4 is —OH or -OAc; R2 is a halogen atom, —OH, or -OAc; and R5 is —CH3, —C?CH, —C?CCH3, or —CH2C?CH.

Abstract: A radiation dosimetry sol or gel, and a radiation dosimeter containing the sol or the gel as a material for radiation dosimetry. A radiation dosimetry sol or gel including a compound (A) having an excitation light-induced fluorescence property that is changed by a radiolysis product of water; and a silicate salt (B). A radiation dosimetry sol or gel including a compound (A) having an excitation light-induced fluorescence property that is changed by a radiolysis product of water; a silicate salt (B); a water-soluble organic polymer (C) having an organic acid salt structure or an organic acid anion structure; and a dispersant (D) for the silicate salt (B). A radiation dosimeter including, as a material for radiation dosimetry, the above-mentioned radiation dosimetry sol or gel.

Abstract: The display system includes a first storage unit storing standardized data composed chromaticity values and luminance values. An information acquirer acquires luminance values and chromaticity values of a visual target and luminance and chromaticity values of a background thereof. A standardization unit standardizes the chromaticity values and the luminance values of the visual target and the background based on these chromaticity values and the luminance values of the visual target and the background thereof and the standardized data stored in the first storage unit. A visual target contrast calculator calculates a contrast of a visual target to a background by measuring a distance in a color space between the visual target and the background each defined by the standardized luminance and chromaticity values. A second storage unit stores an expression defining a relation between the contrast thereof to the background and a size of the visual target.